A workgroup will be convened to modify the TreeExtraction code and TreeScan software to allow for differential follow-up time and making the searching risk window parameters more flexible. The HPV4 vaccine will serve as the test case for the new capability, and will be run on internal test data for two follow-up periods: 6 months and 12 months.
Judith C. Maro, PhD, MS; Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA
Steven A. Anderson, PhD, MPP; Rositsa Dimova, PhD, MS; Adamma Mba-Jonas, MD, MPH; Azadeh Shoaibi, PhD, MHS, MS; Jawahar Tiwari, PhD; Center for Biologics Evaluation and Research, FDA, Silver Spring, MD
David Cole, BM; Meighan Rogers Driscoll, MPH; Austin Cosgrove, BS; Inna Dashevsky, MS; Megan Reidy, MPH; Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA
Martin Kulldorff, PhD; Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA